A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy

The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.

Trial Details

NCT ID
NCT07823322
Phase
PHASE2
Sponsor
Incyte Corporation
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • INCA33890
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Glendale, California, United States|34.14251,-118.25508
  • Irvine, California, United States|33.66946,-117.82311
  • Zion, Illinois, United States|42.44613,-87.83285
  • Rockville, Maryland, United States|39.084,-77.15276

Key Eligibility Criteria

  • Received curative-intent (R0) resection of histologically confirmed Stage II or III colorectal adenocarcinoma.
  • Completed all neoadjuvant and/or adjuvant chemotherapy, including at least 3 months of fluoropyrimidine-based chemotherapy.
  • Has minimal residual disease (MRD), defined as ctDNA positive by the Signatera™ assay (whole exome sequencing \[WES\] or whole genome sequencing \[…
  • 2 weeks and 12 months after completion of adjuvant chemotherapy or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →